FDA Approves CIRCA’s Novel PeriCross™ Epicardial Access Kit

CIRCA Scientific has announced that its PeriCross™ Epicardial Access Kit has received 510(k) clearance from the U.S. Food and Drug Administration. The device is specifically developed to support reliable and efficient access to the pericardial space using a subxiphoid approach.

Gaining epicardial access can be one of the more technically challenging aspects of various electrophysiology and structural heart interventions. The PeriCross system's aim is to address these challenges with a unique design that includes a tine-based retraction feature and a 21-gauge micro-puncture needle. 

This mechanism allows the space between the pericardium and myocardium to be gently separated before the needle advances, offering better control, improved consistency, and smoother procedural workflow.

Initial clinical data from the EASY-R (Epicardial Access Study with Rook) trial involving 21 patients have shown promising results:

  • A 100% success rate in accessing the pericardial space
  • Average access time of 3.5 ± 2.2 minutes, with nearly 40% of cases completed in 2 minutes or less
  • Fluoroscopy averaging 2.1 ± 1.1 minutes
  • Minimal contrast usage, at just 0.7 ± 0.2 mL per case

The FDA clearance marks an important step forward for CIRCA Scientific’s CardioCentric™ strategy, aimed at delivering advanced tools that simplify complex cardiac procedures and improve outcomes.